What's Behind The Big Stock Moves? SPRO, TIL, IMAB....

Several biotech firms saw significant stock movement following recent updates: Spero Therapeutics surged nearly 200% after positive Phase 3 results for tebipenem HBr in cUTIs, prompting an early study stop and planned regulatory submission in 2025. Instil Bio rose 19% on progress with its bispecific antibody '2510 for NSCLC, with Phase 2 data expected in late 2025 and a U.S. trial planned. Annovis Bio gained over 18% as its Phase 3 trial of buntanetap for early Alzheimer's disease enrolled its first patients, while I-Mab Biopharma increased by 21% after prioritizing its givastomig program and reporting enrollment ahead of schedule for its Phase 1b study in gastric cancer.

Analysis

Spero Therapeutics (SPRO) experienced a significant stock surge of over 198% following positive pivotal Phase 3 PIVOT-PO study results for tebipenem HBr in complicated urinary tract infections; the study met its primary endpoint, leading to an early stop for efficacy based on an independent data monitoring committee's recommendation, with GSK planning a U.S. regulatory submission in the second half of 2025. Instil Bio (TIL) shares rose 19% after providing updates on its PD-L1xVEGF bispecific antibody '2510, with its Phase 2 trial in first-line NSCLC in China on track to complete enrollment by Q3 2025 and initial results expected in the second half of 2025, complemented by a monotherapy trial showing a 23% response rate and plans for a U.S. Phase 1b/2 trial before year-end. Annovis Bio (ANVS) shares increased over 18.43% as it enrolled the first patients in its pivotal Phase 3 trial for buntanetap in early Alzheimer's disease and secured a U.S. patent for the drug candidate; the company reported a Q1 2025 net loss of $5.5 million, or $0.32 per share, compared to a net loss of $1.1 million, or $0.72 per share, in Q1 2024, while R&D expenses decreased to $5.0 million from $6.5 million year-over-year. I-Mab Biopharma (IMAB) saw its shares climb 21.15%, driven by the prioritization of its givastomig program for gastric cancer, which is enrolling ahead of schedule in its Phase 1b dose expansion study, with new combination data expected at ESMO GI Congress in July 2025; I-Mab reported a significantly reduced Q1 2025 net loss of $3.2 million, down from $16.3 million in Q1 2024, with R&D expenses falling to $0.8 million from $6.1 million year-over-year. Conversely, Forte Biosciences (FBRX) shares declined 5.33% amidst preparations to release topline data this quarter from its Phase 2 trial of FB-102 for celiac disease; Forte reported an increased Q1 2025 net loss of $15.7 million, or $1.37 per share, compared to a net loss of $7.4 million, or $4.03 per share, in Q1 2024, with R&D expenses rising to $12.7 million from $4.4 million year-over-year.

Key Decisions for Investors

• Spero Therapeutics' positive Phase 3 data for tebipenem HBr and planned regulatory submission by GSK represent a significant de-risking event, potentially warranting a re-evaluation of its valuation and outlook.
• Investors should closely monitor upcoming clinical trial readouts and data presentations for Instil Bio (H2 2025 NSCLC data), Annovis Bio (Phase 3 Alzheimer's progress), and I-Mab Biopharma (July 2025 ESMO GI data for givastomig) as these are key catalysts for near-term stock performance.
• Forte Biosciences' upcoming Phase 2 topline data for FB-102 in celiac disease is a critical binary event; investors should carefully weigh this potential outcome against its increased Q1 2025 net loss and R&D expenditures.
• The contrasting financial positions, with Annovis Bio and I-Mab Biopharma reporting reduced net losses and R&D spend versus Forte Biosciences' increased burn rate, underscore the importance of assessing capital efficiency and financial runway alongside clinical prospects in the biotech sector.